Canada - inglese - Health Canada

fresenius kabi canada ltd - zinc (zinc sulfate) - solution - 1mg - zinc (zinc sulfate) 1mg

Canada - inglese - Health Canada

fresenius kabi canada ltd - zinc (zinc sulfate) - solution - 5mg - zinc (zinc sulfate) 5mg

Israele - inglese - Ministry of Health

medison pharma ltd - mecasermin - solution for injection - mecasermin 10 mg / 1 ml - mecasermin - for the long-term treatment of growth failure in children and adolescents from 2 to 18 years with confirmed severe primary insulin-like growth factor-1 deficiency (primary igfd).severe primary igfd is defined by:* height standard deviation score ≤–3.0and* basal igf-1 levels below the 2.5th percentile for age and genderand* gh sufficiency.* exclusion of secondary forms of igf-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids.severe primary igfd includes patients with mutations in the gh receptor (ghr), post-ghr signaling pathway, and igf-1 gene defects; they are not gh deficient, and therefore, they cannot be expected to respond adequately to exogenous gh treatment.in some cases, when deemed necessary, the physician may decide to assist in the diagnosis by performing an igf-i generation test.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - propantheline bromide 15mg;  ; propantheline bromide 15mg - tablet - 15 mg - active: propantheline bromide 15mg   excipient: calcium carbonate carnauba wax castor oil cosmetic red oxide no 6205 cosmetic red ochre no 1624 lactose monohydrate light liquid paraffin magnesium carbonate magnesium stearate maize starch purified talc saccharin sodium sucrose titanium dioxide yellow beeswax active: propantheline bromide 15mg excipient: lactose monohydrate magnesium stearate maize starch opadry orange 85g63218 purified talc - pro-banthine is indicated as an adjunctive therapy in the treatment of peptic ulcer (gastric and duodenal) and for the relief of the symptoms of gastritis. pro-banthine is also indicated for the symptomatic treatment of the irritable bowel syndrome (irritable colon, spastic colon, mucous colitis, acute enterocolitis, nervous diarrhoea and functional gastrointestinal disorders). other indications include renal colic, hyperhidrosis, as adjunctive therapy in ulcerative colitis, diverticulitis, cholecystitis and pancreatitis and for certain gastrointestinal diagnostic procedures.

Irlanda - inglese - HPRA (Health Products Regulatory Authority)

elanco animal health, eli lilly and company limited - feline enteritis (panleucopenia) virus (fpv), snow leopard strain live attenuated, feline rhinotracheitis virus (fvr), strain fvrm live attenuated, feline calicivrus, strain f9 live attenuated - lyophilisate and solvent for solution for injection - unknown - feline panleucopenia virus / parvovirus vaccine + feline rhinotracheitis virus vaccine + feline cal - feline - immunological - live vaccine

Australia - inglese - Department of Health (Therapeutic Goods Administration)

noumed pharmaceuticals pty ltd - pseudoephedrine hydrochloride, quantity: 30 mg; chlorphenamine maleate, quantity: 2 mg; paracetamol, quantity: 500.4 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; magnesium stearate; crospovidone; pregelatinised maize starch; povidone; purified water; erythrosine aluminium lake; stearic acid - temporary relief of the symptoms of sinus headache, pain and nasal congestion (including fever) and hay fever.

Australia - inglese - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - zinc chloride, quantity: 5.3 mg/ml - injection, concentrated - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - zinc chloride injection is intended for use as an additive to compatible intravenous fluids or total parenteral nutrition solutions. it is indicated for the prevention and treatment of zinc deficiency, which may be characterised by growth deterioration, skin lesions, alopecia, impaired reproductive development and function, and delayed or inhibited wound healing.

Stati Uniti - inglese - NLM (National Library of Medicine)

meda pharmaceuticals - azelastine hydrochloride (unii: 0l591qr10i) (azelastine - unii:zqi909440x) - astelin nasal spray is indicated for the treatment of the symptoms of seasonal allergic rhinitis in adults and pediatric patients 5 years and older, and for the treatment of the symptoms of vasomotor rhinitis in adults and adolescent patients 12 years and older. none. limited data from postmarketing experience over decades of use with astelin in pregnant women have not identified any drug associated risks of miscarriage, birth defects, or other adverse maternal or fetal outcomes. in animal reproduction studies, there was no evidence of fetal harm at oral doses approximately 5 times the clinical daily dose.  oral administration of azelastine hydrochloride to pregnant mice, rats, and rabbits, during the period of organogenesis, produced developmental toxicity that included structural abnormalities, decreased embryo-fetal survival, and decreased fetal body weights at doses 270 times and higher than the maximum recommended human daily intranasal dose (mrhdid) of 1.096 mg. however, the relevance of these findings

Stati Uniti - inglese - NLM (National Library of Medicine)

theratechnologies inc. - tesamorelin acetate (unii: lgw5h38ve3) (tesamorelin - unii:mqg94m5eeo) - egrifta is indicated for the reduction of excess abdominal fat in hiv-infected adult patients with lipodystrophy. limitations of use: - long-term cardiovascular safety of egrifta has not been established. consider risk/benefit of continuation of treatment in patients who have not had a reduction in visceral adipose tissue. - egrifta is not indicated for weight loss management as it has a weight neutral effect. - there are no data to support improved compliance with anti-retroviral therapies in hiv-positive patients taking egrifta egrifta is contraindicated in patients with: - disruption of the hypothalamic-pituitary axis due to hypophysectomy, hypopituitarism, pituitary tumor/surgery, head irradiation or head trauma. - active malignancy. any preexisting malignancy should be inactive and its treatment complete prior to instituting therapy [see warnings and precautions (5.1)] . - known hypersensitivity to tesamorelin or the excipients in egrifta [see warnings and precautions (5.5)]. - pregnant women because mod

Stati Uniti - inglese - NLM (National Library of Medicine)

physicians total care, inc. - azelastine hydrochloride (unii: 0l591qr10i) (azelastine - unii:zqi909440x) - azelastine hydrochloride 137 ug - astelin® nasal spray is indicated for the treatment of the symptoms of seasonal allergic rhinitis such as rhinorrhea, sneezing, and nasal pruritus in adults and children 5 years and older, and for the treatment of the symptoms of vasomotor rhinitis, such as rhinorrhea, nasal congestion and postnasal drip in adults and children 12 years and older. astelin® nasal spray is contraindicated in patients with a known hypersensitivity to azelastine hydrochloride or any of its components. for intranasal use only important: follow instructions carefully to ensure proper dosing. dosing: the dosage of astelin® nasal spray is 1 spray per nostril twice daily for pediatric patients (ages 5-11 years) with seasonal allergic rhinitis. for patients age 12 and older with seasonal allergic rhinitis the dosage is one or two sprays per nostril twice daily. for patients age 12 and older with nonallergic vasomotor rhinitis the dosage is two sprays per nostril twice daily. keep your head tilted downward when spraying. alternate s